Anthony Bergmann Sells 25,000 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 25,000 shares of the company’s stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total value of $753,250.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at approximately $247,758.99. This trade represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Capricor Therapeutics Trading Up 5.0%

Shares of NASDAQ:CAPR traded up $1.50 during mid-day trading on Thursday, reaching $31.62. The stock had a trading volume of 346,173 shares, compared to its average volume of 1,371,751. The firm has a 50 day simple moving average of $27.04 and a two-hundred day simple moving average of $18.74. Capricor Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $40.37. The firm has a market cap of $1.82 billion, a PE ratio of -13.99 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). On average, equities analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. iA Financial set a $48.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. B. Riley Financial boosted their target price on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Piper Sandler reaffirmed an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Finally, UBS Group set a $50.00 price objective on Capricor Therapeutics in a research report on Monday, December 15th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.09.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors have recently added to or reduced their stakes in CAPR. Suvretta Capital Management LLC acquired a new position in Capricor Therapeutics in the 4th quarter worth $51,533,000. Tang Capital Management LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $49,062,000. RA Capital Management L.P. acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth about $43,516,000. Darwin Global Management Ltd. acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth about $23,168,000. Finally, SB Capital Management Inc bought a new position in shares of Capricor Therapeutics during the fourth quarter worth about $11,544,000. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.